Janice Pan
Eisai
7 Papers
21 Citations
Janice Pan is an academic researcher from Eisai. The author has contributed to research in topics: Lenvatinib & Renal cell carcinoma. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
Robert J. Motzer,Camillo Porta,Boris Alekseev,Sun Young Rha,Toni K. Choueiri,María José Méndez-Vidal,Sung-Hoo Hong,Anil Kapoor,Jeffrey C. Goh,Masatoshi Eto,Jinyi Wang,Janice Pan,Alemseged Ayele Asfaw,Cixin Steven He,Kalgi Mody,David Cella +15 more
TL;DR: Overall changes from baseline at mean follow-up (wk 46) favored LEN + PEMBRO with significant differences between treatments for physical functioning, dyspnea, appetite loss and EQ-5D VAS, and overall HRQoL.
21
Metastatic Renal Cell Cancer: An Analysis of Reimbursement Decisions
TL;DR: There remains an unmet need in patients with metastatic renal cell carcinoma despite the many treatment guidelines and current treatment options available, and the key reason for a drug not obtaining a positive reimbursement decision is due to poor efficacy or uncertainty of the drug’s efficacy.
6
Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.
Cristiane Decat Bergerot,Sun Young Rha,Sumanta K. Pal,Piotr Koralewski,Daniil Stroyakovskiy,Boris Alekseev,Francis Parnis,Daniel Castellano,Jae-Lyun Lee,Kaisa Sunela,Tudor Ciuleanu,Daniel Y.C. Heng,Hilary Glen,Jinyi Wang,Lee Bennett,Janice Pan,Karen O'Hara,Javier Puente +17 more
TL;DR: Achievement of health-related quality of life (HRQOL) in patients with Renal cell carcinoma is a major concern and a major need for further research into this disease.
1
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
Cristiane Decat Bergerot,Sun Young Rha,Sumanta K. Pal,Piotr Koralewski,Daniil Stroyakovskiy,Boris Alekseev,Francis Parnis,Daniel Castellano,Jae Lyun Lee,Kaisa L. Sunela,Tudor Ciuleanu,Daniel Y.C. Heng,Hilary Glen,Jinyi Wang,Lee Bennett,Janice Pan,Karen O'Hara,Javier Puente +17 more
TL;DR: People who received an 18 mg lenvatinib starting dose had favorable HRQOL scores and longer TTD on most scales compared with those who received a 14 mg starting dose, and differences between treatments did not exceed the minimally important thresholds.
CO36 Network Meta-Analysis (NMA) to Assess Comparative Efficacy of Lenvatinib Plus Pembrolizumab Compared with Other First-Line Treatments for Management of Advanced Renal Cell Carcinoma (ARCC)
Anirudha V. Kadambi,A. Pandey,B. R. Neupane,Kyle Fahrbach,Sanjay Purushotham,M.J. Jones,Samitha Egodage,Arpit Kashyap,Janice Pan +8 more
TL;DR: The CLEAR trial showed statistically significant improvements in overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and complete response (CR) in subjects treated with lenvatinib plus pembrolizumab (LEN+PEM) vs. sunitinib as discussed by the authors .